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Abstract
Background:	Gastroprokinetic	properties	of	5-	HT4 receptor agonists, such as prucalo-
pride, are attributed to activation of 5- HT4 receptors on cholinergic nerves innervating 
smooth muscle in the gastrointestinal smooth muscle layer, increasing acetylcholine 
release and muscle contraction. In porcine stomach and colon, phosphodiesterase 
(PDE)	4	has	been	shown	to	control	the	signaling	pathway	of	these	5-	HT4 receptors. 
The aim of this study was to investigate the PDE- mediated control of these 5- HT4 
receptors in human large intestine.
Methods: Circular smooth muscle strips were prepared from human large intestine; 
after incubation with [³H]- choline, electrically induced tritium outflow was determined 
as a measure for acetylcholine release. The influence of PDE inhibition on the facilitat-
ing effect of prucalopride on electrically induced acetylcholine release was studied.
Key Results: The non- selective PDE inhibitor IBMX enhanced the facilitating effect of 
prucalopride on electrically induced acetylcholine release. The selective inhibitors vin-
pocetine	 (PDE1),	 EHNA	 (PDE2)	 and	 cilostamide	 (PDE3)	 did	 not	 influence,	 while	
rolipram	and	roflumilast	(PDE4)	enhanced	the	prucalopride-	induced	facilitation	to	the	
same extent as IBMX.
Conclusions & Inferences: In human large intestinal circular muscle, the intracellular 
pathway of 5- HT4 receptors facilitating cholinergic neurotransmission to large intesti-
nal circular smooth muscle is controlled by PDE4. If the synergy between 5- HT4 re-
ceptor agonism and PDE4 inhibition is confirmed in a functional assay with electrically 
induced cholinergic contractions of human large intestinal circular smooth muscle 
strips, combination of a selective 5- HT4 receptor agonist with a selective PDE4 inhibi-
tor	might	enhance	the	in	vivo	prokinetic	effect	of	the	5-	HT4 receptor agonist in the 
large intestine.
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1  | INTRODUCTION
5- HT4	receptor	agonists	are	used	for	gastrointestinal	(GI)	hypomotility	
disorders such as gastroparesis and constipation.1	Their	GI	prokinetic	
effects are attributed to activation of 5- HT4 receptors on cholinergic 
neurons innervating the smooth muscle layer.2 These receptors, facili-
tating	acetylcholine	release	and	GI	contraction,	were	first	shown	in	the	
GI	tract	of	the	guinea-	pig3,4 and later of several species as rat,5 dog,6,7 
pig,8,9 and man.6,10-12 5- HT4 receptors are also present in porcine 
and human atria.13 The highly selective 5- HT4 receptor agonist pru-
calopride,	which	is	marketed	for	chronic	idiopathic	constipation,	only	
induces	a	weak	and	transient	 inotropic	effect	 in	porcine	and	human	
atrial tissue.14,15 5- HT4	 receptors	 are	Gs protein- coupled receptors, 
linked	to	adenylyl	cyclase	and	signaling	via	generation	of	the	second	
messenger	cAMP.	The	weak	response	to	5-	HT4 receptor agonism in 
cardiac	tissue	is	due	to	the	pronounced	control	of	the	cAMP	signal	by	
phosphodiesterases	(PDEs),	degrading	cAMP	and	limiting	the	effect	of	
5- HT4 receptor agonists
15. This regulation is mediated by PDE3 plus 
PDE4 in porcine heart16,17 and by PDE3 in human heart.16,18
The facilitation of enteric cholinergic neurotransmission by pru-
calopride	 in	 the	 porcine	 and	 human	 GI	 tract	 is	 pronounced	 and	
sustained.6,19-21 Still, this effect was shown to be enhanced by the se-
lective PDE4 inhibitor rolipram in porcine stomach and colon.9,22 We 
recently confirmed this23 with the selective PDE4 inhibitor roflumilast, 
marketed	for	chronic	obstructive	pulmonary	disease,24 and the highly 
selective 5- HT4 receptor agonist velusetrag,
25 that is actually under 
clinical development. These results demonstrate that the intracellular 
pathway of the 5- HT4 receptors on the myenteric cholinergic neurons 
in	the	porcine	GI	tract	is	controlled	by	PDE4.	If	confirmed	in	humans,	
combination of a 5- HT4 receptor agonist with a selective PDE4 in-
hibitor	might	 thus	enhance	the	gastroprokinetic	effect	of	 the	5-	HT4 
receptor agonist without potentiation of its cardiac effects, which are 
controlled by PDE3.
The aim of the present study was therefore to investigate whether 
the signal transduction pathway of 5- HT4 receptors in myenteric cho-
linergic neurons innervating human large intestinal circular muscle is 
controlled by PDEs, and if so whether PDE4 is the isozyme involved. 
This was done by measuring the influence of PDE inhibitors on the 
facilitating effect of prucalopride on electrically induced acetylcholine 
release.
2  | MATERIALS AND METHODS
2.1 | Patients and tissue preparation
The	study	was	approved	by	the	Ethical	Committee	of	Ghent	University	
Hospital.	All	patients	(n=59),	including	17	women/42	men	with	a	mean	
age of 66±2 years, provided written informed consent and underwent 
resection of the large intestine because of cancer.
A	specimen	from	the	macroscopic	healthy	segment	of	the	resected	
large	 intestinal	 tissue	 (3	 caecum,	 5	 ascending,	 9	 transverse,	 7	 de-
scending,	20	sigmoid	colon,	and	15	rectum)	was	placed	in	oxygenated	
(95%	 O2+5%	 CO2)	 ice-	chilled	 Krebs-	Henseleit	 solution	 (composi-
tion	 in	mmol	L–1:	NaCl	118.0,	KCl	4.69,	MgSO4	1.18,	KH2PO4 1.18, 
CaCl2 2.51, glucose 11.1, and NaHCO3	25.0)	and	transported	to	the	
laboratory.	 Adipose	 tissue,	 adhering	 mesentery	 and	 mucosa	 were	
removed by blunt dissection and the tissue was stored overnight in 
Krebs-	Henseleit	solution	at	4	°C.	Within	24	hours	after	surgery,	four	
full	thickness	intertaenial	smooth	muscle	strips	of	approximately	1	to	
1.5 cm in length and 0.3 cm in width were cut in the direction of the 
circular smooth muscle from each human large intestinal specimen to 
study acetylcholine release.
2.2 | Measuring acetylcholine release
Circular smooth muscle strips were mounted vertically between two 
platinum	wire	electrodes	(40	×	0.5	mm,	4	mm	apart)	under	a	 load	of	
2	g	in	organ	baths	(2	mL)	filled	with	oxygenated	Krebs-	Henseleit	so-
lution	 from	 now	 on	 containing	 choline	 (1.5	μmol	 L–1),	 ascorbic	 acid	
(57	μmol	L–1),	and	guanethidine	(4	μmol	L–1)	at	37	°C.	During	1	hour	
of	equilibration,	the	tissues	were	superfused	(2	mL	min–1)	with	Krebs-	
Henseleit	solution	using	a	peristaltic	pump	(Minipuls	3;	Gilson	S.A.S.,	
Villiers	 le	 Bel,	 France).	 The	 last	 20	minutes,	 continuous	 electrical	
field	stimulation	(EFS;	1	millisecond	monophasic	square	wave	pulses,	
40	V,	0.5	Hz)	was	applied	by	means	of	a	stimulator	(Grass	S88;	Grass	
Technologies,	West	Warwick,	RI,	USA)	with	a	constant	voltage	unit.
After	superfusion	was	stopped,	the	cholinergic	transmitter	stores	
were labeled by incubating the tissues with [3H]-	choline	(5	μCi	mL–1)	
Key Points
• In porcine stomach and large intestine, phosphodiester-
ase	(PDE)	4	has	been	shown	to	control	the	signaling	path-
way of 5-HT4 receptors on cholinergic nerves innervating 
the smooth muscle layer; this was now investigated in the 
human large intestine.
• In human large intestinal circular smooth muscle strips, 
the facilitating effect of the 5-HT4 receptor agonist pru-
calopride on electrically induced acetylcholine release 
was enhanced by non-selective PDE inhibition with 
IBMX. The selective PDE4 inhibitors rolipram and roflu-
milast	mimicked	 the	effect	of	 IBMX,	while	 inhibitors	of	
PDE1	 (vinpocetine),	 PDE2	 (EHNA),	 and	 PDE3	 (cilosta-
mide)	did	not.
• The signaling pathway of 5-HT4 receptors facilitating 
cholinergic neurotransmission toward human large intes-
tinal circular smooth muscle is thus controlled by PDE4. If 
the synergy between 5-HT4 receptor agonism and PDE4 
inhibition is confirmed in a functional assay with electri-
cally induced cholinergic contractions, combination of a 
5-HT4 receptor agonist with a selective PDE4 inhibitor 
might	 also	 in	 vivo	 enhance	 the	prokinetic	 effect	 of	 the	
5-HT4 receptor agonist.
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under	continuous	EFS	(1	millisecond,	40	V,	2	Hz)	for	30	minutes.	EFS	
and incubation were stopped and loosely bound radioactivity was 
washed-	out	by	superfusing	(2	mL	min–1)	the	tissues	for	90	minutes	with	
Krebs-	Henseleit	 solution	 from	 now	 on	 also	 containing	 hemicholini-
um-	3	(10	μmol	L–1),	physostigmine	(10	μmol	L–1),	and	atropine	(1	μmol 
L–1)	 to	prevent	 re-	uptake	of	choline,	hydrolysis	of	acetylcholine	and	
auto- inhibition of acetylcholine release respectively.
After	ending	superfusion	for	wash-	out,	the	organ	baths	were	filled	
with	1	mL	Krebs-	Henseleit	solution.	The	organ	bath	content	was	col-
lected and replaced every 3 minutes for a total of 35 samples. EFS 
(1	millisecond,	15	V,	4	Hz)	was	applied	twice	for	2	minutes	(S1 and S2):	
S1 started at the 13
th	(sample	5)	and	S2 at the 73
rd	(sample	25)	minute	
after finishing the wash- out period. Drugs were added before S2 and 
remained present until the end of the experiment: PDE inhibitors or 
their solvent from the 37th	minute	(sample	13;	36	minutes	before	S2)	
and prucalopride from the 58th	minute	(sample	20;	15	minutes	before	
S2).	Tissue	strips	were	blotted	and	weighed	at	the	end	of	sample	col-
lection	(28.75±1.48	mg	for	the	184	strips	included	in	the	results).
0.5	mL	of	each	sample	was	mixed	with	2	mL	scintillator	containing	
solution	Ultima	Gold	(Perkin	Elmer,	Waltham,	MA,	USA).	Total	tritium	
outflow	was	measured	as	disintegrations	per	minute	 (dpm)	by	 liquid	
scintillation	counting	(Packard	Tri-	Carb	2100	TR;	Packard	Instrument	
Company,	Downers	Grove,	 IL,	USA)	with	external	standardization	to	
correct for counting efficiency. Total tritium outflow, containing [3H]- 
acetylcholine, [3H]- phosphorylcholine and [3H]- choline, can be con-
sidered	as	a	marker	for	acetylcholine	release	as	we	previously	showed	
by separation of the three radioactive compounds that EFS predom-
inantly increases [3H]- acetylcholine release and that EFS- induced 
changes in total tritium outflow parallel those in [3H]- acetylcholine.12
2.3 | Experimental protocols and design
In four separate series, the influence of 10 μmol	 L–1	 IBMX	 (non-	
selective	PDE	inhibitor)	on	the	effect	of	0.03	μmol	L–1 prucalopride and 
the influence of 10 μmol	L–1 IBMX, 1 μmol	L–1 rolipram or 0.3 μmol	L–1 
roflumilast	(both	selective	PDE4	inhibitors)	on	the	effect	of	0.01	μmol 
L–1	prucalopride	was	studied.	Four	parallel	strips	 (same	patient)	were	
used for each series: either PDE inhibitor alone, prucalopride alone, or 
prucalopride in the presence of the PDE inhibitor was added before S2; 
the fourth control strip did not receive active compounds.
The influence of 100 μmol	 L–1	 vinpocetine	 (PDE1	 inhibitor),	
30 μmol	L–1	EHNA	(PDE2	inhibitor)	and	1	μmol	L–1	cilostamide	(PDE3	
inhibitor)	on	the	effect	of	0.01	μmol	L–1 prucalopride was studied in a 
fifth series with four parallel strips: one with administration of pruca-
lopride alone, and three where prucalopride was added after previous 
administration	of	vinpocetine,	EHNA	or	cilostamide.
In two final series the solvent of IBMX, ethanol, and of vinpoce-
tine, cilostamide, rolipram and roflumilast, DMSO, was tested in the 
highest concentration used upon administration of the PDE inhibitors: 
0.05%	for	ethanol	and	1%	for	DMSO.	Their	possible	influence	on	the	
effect of prucalopride was tested by four parallel strips receiving the 
solvent alone, prucalopride alone, prucalopride in the presence of the 
solvent and a control not receiving active compounds.
The four experimental conditions per series were rotated over the 
four organ baths from experiment to experiment.
2.4 | Data and statistical analysis
EFS induced a clear- cut increase in tritium outflow, by S1 in samples 
5 up to 7 and by S2 in samples 25 up to 27. The EFS- induced increase 
in tritium outflow was determined by subtracting the corresponding 
basal tritium outflow, which was calculated by fitting a regression line 
through the values of four samples just before stimulation and the 
values of the four samples starting from the sixth sample after stimu-
lation. S2/S1 ratio was then calculated: the sum of the tritium outflow 
above baseline of samples 25 to 27 as ratio of the sum of the tritium 
outflow above baseline of samples 5 to 7.
Strips were excluded from analysis when: the S1- and/or S2- 
induced	release	peak	showed	an	aberrant	pattern	eg	double	peak	(24	
out	of	236	strips),	the	basal	outflow	was	unstable	(18	out	of	236	strips)	
or	a	technical	defect	occurred	mainly	a	defect	of	electrodes	 (10	out	
of	236	strips)	meaning	 that	 the	 results	of	184	strips	are	given.	This	
exclusion from data analysis also explains unequal group sizes within 
an experimental series.
Data are expressed as mean±SEM and n refers to the number of 
tissues	obtained	 from	different	patients.	As	data	were	homogenous	
(Levene’s	 test),	 they	 were	 compared	 by	 one-	way	 ANOVA	with	 un-
paired t tests with Bonferroni correction for multiple comparisons; 
the Bonferroni corrected t	tests	were	only	conducted	if	the	ANOVA	
showed significance. P-values less than .05 were considered statis-
tically	 significant.	 Statistical	 analysis	was	 performed	with	 GraphPad	
Prism	version	5.03	(GraphPad	Software,	San	Diego,	CA,	USA).
2.5 | Drugs
L-	ascorbic	 acid,	 atropine	 sulfate	 salt,	 choline	 chloride,	 guanethidine	
sulfate, hemicholinium- 3 bromide, 3- isobutyl- 1- methylxanthine 
(IBMX),	 eserine	 salicylate	 salt	 (physostigmine),	 roflumilast	were	 ob-
tained	from	Sigma-	Aldrich	(St.	Louis,	MO,	USA);	cilostamide,	erythro-	
9-	(2-	hydroxy-	3-	nonyl)adenine	 (EHNA)	 hydrochloride,	 rolipram,	
vinpocetine	from	Tocris	Bioscience	(Bristol,	UK);	[methyl-	3H]- choline 
chloride	from	Perkin	Elmer	(Boston,	MA,	USA)	and	prucalopride	suc-
cinate	from	Selleck	Chemicals	(Houston,	TX,	USA).
Drugs were dissolved and diluted in distilled water, except for 
IBMX which was dissolved in ethanol, yielding a concentration of 
0.05%	in	the	organ	bath,	and	vinpocetine,	cilostamide,	rolipram,	and	
roflumilast which were dissolved in DMSO, yielding a concentration 
of,	respectively	1%,	0.01%,	0.01%,	and	0.003%	in	the	organ	bath.
3  | RESULTS
3.1 | Influence of IBMX on the effect of prucalopride 
(Figures 1 and 2) 
We previously have shown that 0.3 μmol	L–1 prucalopride induces a 
pronounced increase in EFS- induced acetylcholine release in human 
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colon.12,26	A	10-	fold	lower	concentration	of	prucalopride	was	there-
fore used in the first series of the actual study to test the influence 
of 10 μmol	L–1 IBMX. EFS induced a clear- cut increase in tritium out-
flow above the basal level in up to three samples after EFS and at 
the 6th sample after EFS, tritium outflow returned to baseline values 
(Figure	1).	The	S2- induced tritium outflow was lower than that induced 
by S1	 (Figure	1A), yielding a S2/S1 ratio of 0.60±0.03 in the control 
group	(n=9;	Figure	2A).	Prucalopride	and	IBMX	did	not	influence	basal	
tritium	outflow	(Figure	1B	and	1C);	IBMX	had	no	significant	effect	on	
the S2-	induced	tritium	outflow	(n=8;	Figures	1B	and	2A).	Prucalopride	
(0.03	μmol	L–1)	 however	 significantly	enhanced	EFS-	induced	 tritium	
outflow	 (Figure	1C)	 yielding	 a	 S2/S1	 ratio	 of	 0.88±0.04	 (n=10)	 vs	
0.60±0.03	 in	 control	 tissues	 (Figure	2A).	 No	 apparent	 regional	 dif-
ferences	in	the	effect	of	prucalopride	were	observed	(see	Table	S1).	
Prucalopride	(0.03	μmol	L–1)	in	the	presence	of	IBMX	(10	μmol	L–1)	led	
to a S2/S1	ratio	of	0.94±0.05	(n=10),	which	is	somewhat	higher	than	
with prucalopride alone but this increase did not reach significance 
(Figure	2A).
IBMX	(10	μmol	L–1)	was	therefore	tested	vs	a	3-	fold	lower	concen-
tration	of	prucalopride	 (0.01	μmol	L–1).	 In	this	series,	 the	S2/S1 ratio 
was	0.74±0.04	 (n=7)	 in	 the	control	 tissues,	0.76±0.05	 (n=11)	 in	 the	
strips	where	IBMX	alone	was	added	and	0.86±0.03	(n=9)	in	the	strips	
where prucalopride alone was added; this tendency to increase the 
S2/S1 ratio by 0.01 μmol	L
–1 prucalopride did not reach significance 
(Figure	2B).	However,	prucalopride	(0.01	μmol	L–1)	in	the	presence	of	
IBMX	(10	μmol	L–1)	induced	a	pronounced	increase	in	the	S2- induced 
tritium outflow with a S2/S1	ratio	of	1.06±0.07	(n=10),	being	signifi-
cantly different from controls and from strips treated with prucalo-
pride	alone	(Figure	2B).
3.2 | Influence of rolipram and roflumilast on the 
effect of prucalopride (Figures 3 and 4)
Rolipram	 (1	μmol	 L–1)	 did	 not	 influence	 basal	 or	 EFS-	induced	 trit-
ium	 outflow	 (S2/S1	 ratio	 of	 0.72±0.02	 [n=7],	 vs	 0.72±0.03	 [n=9]	
in	 controls;	 Figure	3).	 Prucalopride	 (0.01	μmol	 L–1)	 alone	 did	 not	
significantly	 facilitate	 EFS-	induced	 tritium	 outflow	 (S2/S1 ratio of 
0.78±0.04,	n=8).	In	the	presence	of	rolipram,	prucalopride	(0.01	μmol 
L–1)	induced	a	pronounced	increase	in	EFS-	induced	tritium	outflow	
with a S2/S1	 ratio	of	0.95±0.03	 (n=8),	 being	 significantly	different	
F IGURE  1  Influence of IBMX and prucalopride on basal and electrically induced tritium outflow. Influence of 10 μmol	L–1	IBMX	(B),	
0.03 μmol	L–1	prucalopride	(C),	and	prucalopride	in	the	presence	of	IBMX	(D)	on	basal	and	electrically	induced	total	tritium	outflow;	parallel	
control	tissues	are	shown	in	(A).	Samples	were	collected	every	3	minutes	for	measurement	of	total	tritium	outflow.	Tissues	were	stimulated	
twice	(1	millisecond,	15	V,	4	Hz,	2	minutes)	at	the	5th	(S1)	and	25
th	(S2)	sample	inducing	a	stimulation-	induced	peak	of	the	tritium	outflow	as	
indicated by grey shading; IBMX and prucalopride were added before S2 as indicated by the arrows. Means±SEM are shown
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from that in control strips and in strips where prucalopride alone 
was administered.
This was confirmed with another selective PDE4 inhibitor roflu-
milast that also did not influence basal tritium outflow. Roflumilast 
(0.3	μmol	L–1)	and	prucalopride	 (0.01	μmol	L–1)	alone	had	no	signifi-
cant influence on the EFS- induced tritium outflow with S2/S1 ratios of 
respectively	0.74±0.05	(n=7)	and	0.75±0.03	(n=7)	vs	0.72±0.02	(n=7)	
in	control	tissues	(Figure	4).	Prucalopride	in	the	presence	of	roflumilast	
significantly enhanced the S2/S1	 ratio	 up	 to	 0.98±0.07	 (n=8),	when	
compared with control tissues and tissues receiving prucalopride 
alone. This enhancement in the effect of prucalopride by roflumilast is 
of similar magnitude as that found with rolipram.
F IGURE  2 S2/S1 ratios illustrating the influence of IBMX on  
the effect of prucalopride. Influence of 10 μmol	L–1 IBMX, 0.03  
(A)	and	0.01	(B)	μmol	L–1	prucalopride	(pru),	and	0.03	(A)	and	0.01	
(B)	prucalopride	in	the	presence	of	IBMX	on	the	S2/S1 ratio of 
electrically induced total tritium outflow. Tissues were stimulated 
twice	(S1 and S2;	1	millisecond,	15	V,	4	Hz,	2	minutes);	IBMX	was	
added 36 minutes and prucalopride 15 minutes before S2. Mean  
S2/S1±SEM;	one-	way	ANOVA	followed	by	Bonferroni	corrected	t test 
with ns not significant, *P<.05 and ***P<.001
F IGURE  3 S2/S1 ratios illustrating the influence of rolipram 
on the effect of prucalopride. Influence of 1 μmol	L–1 rolipram 
(roli),	0.01	μmol	L–1	prucalopride	(pru)	and	prucalopride	in	the	
presence of rolipram on the S2/S1 ratio of electrically induced 
total	tritium	outflow.	Tissues	were	stimulated	twice	(S1 and S2; 
1	millisecond,	15	V,	4	Hz,	2	minutes);	rolipram	was	added	36	minutes	
and prucalopride 15 minutes before S2. Mean S2/S1±SEM; one- 
way	ANOVA	followed	by	Bonferroni	corrected	t test with ns not 
significant, **P<.01 and ***P<.001
F IGURE  4 S2/S1 ratios illustrating the influence of roflumilast 
on the effect of prucalopride. Influence of 0.3 μmol	L–1 roflumilast 
(roflu),	0.01	μmol	L–1	prucalopride	(pru)	and	prucalopride	in	the	
presence of roflumilast on the S2/S1 ratio of electrically induced 
total	tritium	outflow.	Tissues	were	stimulated	twice	(S1 and S2; 
1	millisecond,	15	V,	4	Hz,	2	minutes);	roflumilast	was	added	
36 minutes and prucalopride 15 minutes before S2. Mean S2/
S1±SEM;	one-	way	ANOVA	followed	by	Bonferroni	corrected	t test 
with ns not significant, *P<.05 and **P<.01
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3.3 | Influence of vinpocetine, EHNA and cilostamide 
on the effect of prucalopride (Figure 5)
In order to be able to study the three PDE inhibitors in one series, 
there were no control strips without addition of active compounds 
before S2 included, but the strips where prucalopride alone was ad-
ministered were used for comparison. In the presence of prucalopride 
(0.01	μmol	L–1)	a	S2/S1	value	of	0.74±0.03	 (n=5)	was	obtained.	This	
was	not	influenced	by	previous	addition	of	vinpocetine	(100	μmol	L–1),	
EHNA	(30	μmol	L–1),	and	cilostamide	(1	μmol	L–1)	where	S2/S1 ratios 
of	respectively	0.72±0.07	(n=4),	0.72±0.05	(n=6),	and	0.72±0.03	(n=6)	
were	 obtained	 (Figure	5).	 A	 one-	way	ANOVA	did	 not	 reach	 signifi-
cance.	Vinpocetine,	EHNA,	and	cilostamide	had	no	effect	on	the	basal	
tritium outflow.
3.4 | Influence of ethanol and DMSO on the effect of 
prucalopride
The	solvents	were	tested	in	two	small	series.	Ethanol	(0.05%)	did	not	
influence basal tritium outflow. In the presence of ethanol, the S2/S1 
ratio	of	0.64±0.06	(n=3)	was	the	same	as	that	in	controls	(0.64±0.03;	
n=3).	 Prucalopride	 (0.01	μmol	 L–1)	 alone	 led	 to	 a	 S2/S1 ratio of 
0.68±0.07	 (n=3),	which	was	 not	 influenced	 by	 previous	 addition	 of	
ethanol	(S2/S1	ratio	of	0.65±0.08;	n=3).
DMSO	(1%)	had	no	effect	on	basal	and	EFS-	induced	tritium	out-
flow with a S2/S1	ratio	of	0.72±0.05	(n=4)	vs	0.70±0.02	(n=4)	in	con-
trols.	 In	the	presence	of	prucalopride	 (0.01	μmol	L–1)	 the	S2/S1 ratio 
was	0.81±0.07	 (n=4),	which	 is	 comparable	 to	0.83±0.05	 (n=4)	mea-
sured for prucalopride in the presence of DMSO.
4  | DISCUSSION
Prucalopride	(Resolor™),	marketed	for	constipation,	stimulates	whole	
gut transit and colonic transit in healthy humans27,28 and increases 
stool frequency and decreases stool consistency in patients with con-
stipation.29,30	 The	underlying	mechanism	 for	 these	 prokinetic	 prop-
erties of prucalopride and other 5- HT4 receptor agonists is thought 
to be interaction with stimulating 5- HT4 receptors localized on cho-
linergic	neurons	 toward	GI	smooth	muscle,	 facilitating	acetylcholine	
release	 and	 cholinergic	 contraction	 in	 the	GI	 tract.	 This	mechanism	
was clearly shown in human stomach11 and colon12 as prucalopride 
increased electrically induced acetylcholine release, which was an-
tagonized by selective 5- HT4 receptor antagonists confirming inter-
action with 5- HT4 receptors; the facilitating effect of 0.3 μmol	 L
–1 
prucalopride, which is 10- to 30- fold higher than used in this study, 
was	antagonized	by	1	nmol	L–1 SB204070 in human stomach11 and by 
0.01 μmol	L–1	GR	113808	in	human	colon.12 Cardiovascular adverse 
events were reported with the 5- HT4 receptor agonists cisapride and 
tegaserod, but these adverse events are not 5- HT4 receptor- related 
(cisapride	by	interaction	with	human	ether-	a-	go-	go-	related	gene	po-
tassium channels and tegaserod possibly by interaction with 5- HT1 
and/or 5- HT2 receptors
31).	These	cardiovascular	side	effects	should	
thus not occur with the new generation of highly selective 5- HT4 re-
ceptor agonists such as prucalopride. Prucalopride was indeed found 
to be cardiovascularly safe in several randomized placebo- controlled 
double- blind trials in patients with chronic constipation;32 neverthe-
less	 combination	 therapies	 are	 explored	 to	 lower	 the	dose	 and	 risk	
of adverse events. Combination of a 5- HT4 receptor agonist with the 
acetylcholinesterase inhibitor neostigmine had a synergistic effect on 
cholinergic activity in vitro in human colon5 and on colonic transit time 
in vivo in rat;33 the synergistic effect on cholinergic activity in vitro in 
human colon was confirmed with the acetylcholinesterase inhibitor 
donepezil.34 Combination of a 5- HT4 receptor agonist with a PDE4 in-
hibitor might also be considered. 5- HT4	receptors	are	Gs- protein cou-
pled	receptors	linked	to	adenylate	cyclase	and	the	generation	of	the	
second	messenger	cAMP,	and	PDEs	are	the	sole	family	of	 isozymes	
degrading	 cAMP.	A	 tight	 controlling	 role	 of	 the	 signal	 transduction	
of cardiac 5- HT4 receptors was shown: by PDE3 plus PDE4 in the 
porcine heart16,17 and by PDE3 in the human heart.18	As	5-	HT4 recep-
tors enhancing cholinergic neurotransmission in porcine stomach and 
colon are controlled by PDE4, we proposed that combining a 5- HT4 
receptor agonist with a PDE4 inhibitor might enhance its gastropro-
kinetic	effect.9,22,23 The actual study therefore investigated whether 
5- HT4 receptors enhancing cholinergic neurotransmission in human 
large intestine are also controlled by PDEs, by studying the effect of 
PDE inhibition on the facilitating effect of prucalopride on acetylcho-
line release.
In order to be able to observe a possible facilitating influence of 
PDE inhibition on the effect of prucalopride, the influence of 10 μmol 
F IGURE  5 S2/S1 ratios illustrating the influence of vinpocetine, 
EHNA	and	cilostamide	on	the	effect	of	prucalopride.	Influence	
of 0.01 μmol	L–1	prucalopride	(pru)	alone	or	in	the	presence	of	
100 μmol	L–1	vinpocetine	(vinpo),	30	μmol	L–1	EHNA	or	1	μmol	L–1 
cilostamide	(cilo)	on	the	S2/S1 ratio of electrically induced total tritium 
outflow.	Tissues	were	stimulated	twice	(S1 and S2; 1 millisecond, 
15	V,	4	Hz,	2	minutes);	vinpocetine,	EHNA	and	rolipram	were	 
added 36 minutes and prucalopride 15 minutes before S2. Mean  
S2/S1±SEM;	one-	way	ANOVA	did	not	reach	significance
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L–1 of the non- selective PDE inhibitor IBMX, which was shown to be 
effective in enhancing the effect of prucalopride on acetylcholine re-
lease in porcine gastric circular muscle,9 was first tested vs 0.03 μmol 
L–1 prucalopride, a 10- fold lower concentration than the one shown 
before to clearly enhance electrically induced acetylcholine release 
in human colon.12 However this concentration of prucalopride still 
induced a pronounced facilitation of the electrically induced ace-
tylcholine release with a S2/S1	 ratio	of	0.88	(vs	0.60	in	the	control	
group)	which	 is	 in	the	range	of	the	effect	previously	reported	with	
0.3 μmol	 L–1 prucalopride in human colon circular muscle;12,26 the 
effect of 0.03 μmol	L–1 prucalopride was not significantly enhanced 
by IBMX. When further decreasing the prucalopride concentration 
to 0.01 μmol	 L–1, a non- significant increase in S2/S1 ratio to 0.86 
(vs	0.74	in	the	control	group)	was	observed.	But	in	the	presence	of	
IBMX, that had no influence on the electrically induced acetylcholine 
release, 0.01 μmol	L–1 prucalopride significantly enhanced the S2/S1 
ratio to 1.06. This degree of potentiation with IBMX is in agreement 
with the level obtained in porcine stomach circular muscle.9 The ef-
fect of IBMX is not due to an effect of its solvent ethanol, given the 
non- effect of ethanol on electrically induced acetylcholine release 
and its potentiation by prucalopride. The intraneuronal pathway of 
5- HT4 receptors on cholinergic neurons, facilitating acetylcholine re-
lease, in human large intestinal circular muscle is thus also regulated 
by PDEs.
To identify the responsible PDE subtype, selective PDE inhibitors 
were	investigated.	As	cAMP	is	the	cyclic	nucleotide	involved	in	the	5-	
HT4	receptor	pathway,	only	the	cAMP	degrading	classic	PDE	subtypes	
were	investigated:	PDE1,	2	and	3	degrade	both	cAMP	and	cGMP	and	
PDE4	is	cAMP	specific35,36 and are selectively inhibited by respectively 
vinpocetine,	EHNA,	cilostamide,	and	rolipram.37 100 μmol	L–1 vinpo-
cetine, 30 μmol	L–1	EHNA	and	1	μmol	L–1 cilostamide did not influence 
the effect of prucalopride on electrically induced acetylcholine release. 
These concentrations were definitely high enough to inhibit their re-
spective	 PDE	 subtype	 given	 the	 reported	 Ki- values of 14 μmol	 L
–1, 
1 μmol	L–1, and 0.02 μmol	L–1 36 and IC50 values of 8-50 μmol	L
–1 38-40 
1- 5 μmol	L–1 41-43 and 0.005- 0.13 μmol	L–1 35,41,44-46 for, respectively, 
vinpocetine,	EHNA,	 and	cilostamide.	Rolipram	 in	a	 concentration	of	
1 μmol	L–1, which is able to inhibit all PDE4 isozymes,47 did not in-
fluence the electrically induced acetylcholine release, but significantly 
enhanced the effect of prucalopride; this is not related to its solvent 
DMSO that was without effect. The increase in S2/S1 ratio from 0.78 
with	prucalopride	alone	to	0.95	with	prucalopride	in	the	presence	of	
rolipram is of the same magnitude as obtained in the series with IBMX 
(from	0.86	 to	 1.06).	 Roflumilast	 is	 another	 selective	 PDE4	 inhibitor	
which is already used to suppress exacerbations of chronic obstruc-
tive pulmonary disease.24,48,49 Roflumilast, inhibiting the four PDE4 
isozymes with an IC50	of	about	1	nmol		L
–1,50 reached a maximal effect 
in a concentration of 0.3 μmol	L–1 when tested for its enhancement 
of prucalopride- induced facilitation of acetylcholine release in porcine 
stomach.23 In human large intestinal circular smooth muscle, this con-
centration of roflumilast did not influence acetylcholine release, but 
potentiated the facilitating effect of prucalopride to the same extent 
as rolipram with an increase in S2/S1 ratio from 0.75 with prucalopride 
alone	 to	 0.98	with	 prucalopride	 in	 the	 presence	 of	 roflumilast.	The	
results with rolipram and roflumilast illustrate that the intraneuronal 
pathway of acetylcholine release facilitating 5- HT4 receptors, localized 
on cholinergic neurons in human large intestinal circular muscle, is reg-
ulated exclusively by PDE4, just as in the porcine stomach and colon. 
From	 their	 functional	 study	 in	 human	 colon	 circular	 muscle,	 Cellek	
et al.5 suggested possible poor coupling of the 5- HT4 receptor to ace-
tylcholine	release;	this	might	be	related	to	the	regulation	of	the	cAMP	
response to receptor activation by PDE4. In the porcine stomach, ro-
lipram or roflumilast alone enhanced electrically induced acetylcholine 
release23 suggesting that PDE4 constitutively regulates the basal con-
tent	of	cAMP	in	porcine	stomach	cholinergic	neurons.	This	is	not	the	
case in human large intestine, as rolipram or roflumilast alone did not 
influence acetylcholine release.
The 5- HT4 receptor pathway in cholinergic neurons in human 
large intestinal circular muscle is thus also regulated by PDE4. If 
the synergy between 5- HT4 receptor agonism and PDE4 inhibi-
tion as shown here on acetylcholine release can also be obtained 
on EFS- induced cholinergic contraction, in vivo combination ther-
apy of prucalopride or another selective 5- HT4 receptor agonist 
with a selective PDE4 inhibitor can be considered for constipation. 
This combination therapy might allow to use a low dose of the 
5- HT4	 receptor	 agonist,	 while	 the	 prokinetic	 effect	 is	 maintained.	
The recommended dose of prucalopride is 2 mg once daily. In 
healthy	 volunteers,	 taking	 2	mg	 prucalopride	 per	 os	 once	 daily	 for	
7	days,	 pharmacokinetic	 steady	 state	 was	 attained	 within	 3	days	
and the Cmax	 plasma	 concentration	 on	 day	 7	 was	 8.09	ng	 mL
–1, 
at a median time of 2 hours postdose; Cmin and Caverage were 2.21 
and	4.32	ng	mL–1 respectively.51 Similar values were obtained in el-
derly		patients	with	constipation.	Upon	intake	of	0.5,	1	or	2	mg	pru-
calopride	once	daily	for	4	weeks,	steady	state	was	reached	between	
days	4	and	7	of	treatment	and	peak	plasma	concentrations	were	at-
tained 2- 3 hours postdose;52 the near Cmax plasma concentrations 
determined	at	3	hours	postdose	on	day	7	were	2,	4	and	7	ng	mL–1, 
corresponding	to	0.005,	0.011	and	0.019	μmol	L–1. The prucalopride 
concentration of 0.01 μmol	L–1 that shows synergy with PDE4 inhi-
bition in the actual study thus correlates to the Cmax obtained upon 
repeated dosing with 1 mg. When combining a 5- HT4 receptor ago-
nist with a PDE4 inhibitor, the action of the 5- HT4 receptor agonist 
at the level of the cardiac 5- HT4 receptors will not be influenced, be-
cause in the human atrium the 5- HT4 receptor pathway is under sole 
control of PDE3.16 However, the role of PDEs in controlling the cy-
clic nucleotide concentrations at the level of the smooth muscle cells 
in	human	 large	 intestinal	circular	muscle	must	be	 taken	 in	account.	
PDE inhibition might increase the basal level of cyclic nucleotides in-
ducing relaxation. If the PDE involved is PDE4, the PDE4 inhibitor 
in the combination therapy might induce relaxation, counteracting 
the	prokinetic	effect	 in	the	 large	 intestine.	 In	porcine	colon	circular	
muscle the predominant PDE is PDE3.22 In human rectal circular mus-
cle, PDE1, 2, 3, and 4 inhibitors all reduced histamine- induced tone 
suggesting a role for several PDEs.53 In human colon circular muscle, 
both IBMX and rolipram concentration- dependently reduced basal 
tone, rolipram having a smaller maximal effect; other PDE inhibitors 
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were not tested.54	An	elaborated	in	vitro	functional	study	investigat-
ing the effect of PDE inhibitors on cholinergic contractions by electri-
cally released acetylcholine and by an exogenous muscarinic agonist 
in human large intestinal circular muscle can clarify the muscular role 
of PDEs. However, even when the PDE inhibitor alone induces relax-
ation, it is possible to enhance the 5- HT4 receptor- mediated facilita-
tion of cholinergic contraction in a selected concentration range as 
shown before with IBMX in porcine stomach.9 In human colon 5- HT4 
receptors have also been described on circular smooth muscle cells 
and rolipram, in a concentration not influencing basal tone, facilitated 
the relaxant effect of 5- HT via these receptors.54 The possible con-
tribution of these relaxant receptors to the clinical effect of 5- HT4 
receptor agonists such as prucalopride at colonic level, that in vivo 
is	 clear-	cut	 prokinetic,27,28 is not well understood. If relevant, the 
prokinetic	effect	of	a	5-	HT4 receptor agonist might depend on a fine 
balance between its excitatory and inhibitory effects, and facilitation 
of both effects by rolipram might be beneficial. It should be stated 
that the presence of relaxant 5- HT4 receptors in human colon circular 
muscle could not be systematically confirmed;10 they were also not 
observed in porcine colon.8
5  | CONCLUSION AND FUTURE  
PERSPECTIVES
In conclusion, the intraneuronal pathway of 5- HT4 receptors facilitating 
cholinergic neurotransmission in human large intestinal circular muscle 
is,	just	as	in	the	porcine	GI	tract,	controlled	by	PDE4;	PDE4	inhibition	
leads to an enhancement of the facilitating effect of prucalopride on 
acetylcholine release. If this synergy is confirmed in a functional assay 
with	 electrically	 induced	 cholinergic	 contractions,	 the	 in	 vivo	 proki-
netic effect of 5- HT4 receptor agonists in the large intestine might be 
promoted by combination with a selective PDE4 inhibitor; this can be 
further explored as possible combination therapy for gastrointestinal 
hypomotility disorders such as constipation as an alternative option to 
combination with acetylcholinesterase inhibitors. For both combina-
tion strategies safety will have to be evaluated. Muscarinic effects as 
diarrhea, nausea and vomiting and nicotinic ones as muscle cramps 
can occur with acetylcholinesterase inhibitors. The most frequently 
reported adverse events in clinical studies with the PDE4 inhibitor ro-
flumilast for chronic obstructive pulmonary disease also included diar-
rhea and nausea along with weight loss and headache.55
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